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Methods and Results To determine if the failure to lyse pulmonary thromboemboli is caused by an abnormality in the endothelial cell (EC)-associated fibrinolytic system, conditions were established to culture ECs from patient main pulmonary arteries during surgical pulmonary thromboendarterectomies and to analyze the conditioned media for levels of tissue-type plasminogen activator (TPA) and type 1 plasminogen activator inhibitor (PAI-1). Our data indicate that the levels of TPA antigen and PAI-1 activity in media conditioned by primary ECs harvested from areas free of thrombus were not significantly different between patients with chronic thromboemboli P5 ulmonary thromboemboli usually resolve, leading to restoration of normal pulmonary hemodynamics. However, embolic vascular obstruction fails to resolve in 0.1% of cases1 and results in chronic thromboembolic pulmonary hypertension. In contrast to acute pulmonary embolism, chronic thromboembolic pulmonary hypertension is characterized by its clinical quiescence until severe pulmonary hypertension has developed. Moreover, this disease can be distinguished pathologically from primary pulmonary hypertension by the unique presence of highly organized thrombi in the segmental and/or larger elastic pulmonary arteries. 23 Untreated, chronic thromboembolic pulmonary hypertension results in a high mortality rate.4-6 Restoration of pulmonary blood flow by pulmonary thromboendarterectomy has dramatically improved the long-term function and survival of patients with this disorder. 1, [4] [5] [6] [7] [8] [9] [10] Research over the past 30 years has established that fibrin thrombi are degraded in large part by the proteolytic action of plasmin, a serine protease that circulates in plasma as a proenzyme, plasminogen."1 Current and organ donors. In 13 consecutive patients, no correlation was obtained in either the TPA antigen or PAI-1 activity level in a patient's plasma and the respective levels in media conditioned by the patient's pulmonary ECs. Moreover, patient pulmonary arterial ECs were observed to increase the secretion of TPA and PAI-1 in response to thrombin in a fashion similar to donor pulmonary artery ECs.
Conclusions The data suggest that an inherent EC-mediated fibrinolytic imbalance is not a generalized phenomenon observed in pulmonary arteries of patients with chronic pulmonary thromboemboli. Despite the progress that has been made in understanding the biochemistry of the fibrinolytic system, the mechanisms responsible for the persistence of thromboembolic residua in patients with chronic thromboembolic pulmonary hypertension remain to be elucidated. Data from a number of laboratories indicate that the regulation of plasminogen activation plays an important role in a number of biological processes and may occur as a localized event within the vascular wall.18,19 The present study was initiated to determine if the failure to lyse pulmonary emboli is caused by an altered capability of patient pulmonary artery ECs to produce and secrete two key regulators of the fibrinolytic system. In this study, ECs were harvested from pulmonary arteries 20 mmol/L) between 7:00 AM and 9:00 AM on the day of surgery before induction of anesthesia. Donor blood was collected 1 hour before organ explantation. Blood was centrifuged (680g for 15 minutes at 4°C), and the plateletpoor plasma was collected and stored at -70°C.
Specimens from patients with chronic thromboembolic pulmonary hypertension were obtained at pulmonary thromboendarterectomy. In the patients entered into the study, the main pulmonary artery and the lobar and segmental pulmonary arteries were filled with chronic thromboemboli that had become incorporated into the vessel wall, which prevented the harvest of ECs from those sites. Fortunately, in the main pulmonary artery, ECs were available immediately adjacent to the thromboemboli, and these areas were harvested to determine the phenotype of ECs in the immediate proximity of the thromboemboli. Briefly, after pulmonary arteriotomy, ECs were harvested by scraping approximately 1 cm2 of the luminal surface with a surgical blade. The blades were rinsed with 2 mL of complete tissue culture medium, visible EC sheets were carefully broken up by repeated pipetting with a 5-mL pipette, and the resulting mixture was placed onto fibronectin-coated (Sigma Chemical Co) 33-mm tissue culture plates. The samples as described. 23 The bound PAI-1 was detected immunologically24 using an alkaline-phosphatase/polyclonal anti-PAI-1-based system. PAI-1 antigen was quantitated using a two-site immunoassay as described.25
Statistical Analysis
Levels of TPA and PAI-1 in conditioned media were compared using ANOVA. The EC-conditioned media time course studies were analyzed by an ANOVA with repeated measures. Correlation analyses between conditioned media and plasma data were based on the Spearman rank correlation coefficient because the values of plasma samples were not normally distributed. A three-factor ANOVA was used in the interpretation of the thrombin stimulation experiments. The degrees of freedom for the F values in this analysis were corrected according to Greenhouse [Fig 1B] ). Flow-cytometry experiments using Dil-acetylated LDL were used to confirm the purity of the EC cultures ( Fig  1C) , which appear as a single population of bright cells compared with the pattern obtained when human fibroblasts were similarly analyzed (Fig 1D) . Initially, HPDS (20%) was used to grow ECs to achieve an in vitro system that used homologous reagents. Fig 2 demon (Fig 2A, closed bar 3 ) compared with the patients' cells that were cultured in 20% human serum (Fig 2A, Because elevated plasma TPA and PAI-1 levels had been detected in our initial study examining the plasma fibrinolytic system in patients with chronic thromboembolic pulmonary hypertension,21 we performed a parallel analysis of the levels of TPA and PAI-1 in a patient's plasma and the respective levels in conditioned media. No significant correlation was observed between the TPA antigen level in a patient's plasma and the level for this protein in the media conditioned by a patient's pulmonary artery ECs (Table; Spearman r= -.03, P=.9). A similar analysis for PAI-1 activity (Table; Spearman r= -.3, P=.2) and antigen (Table; Spearman r=-.03, P=.9) also indicated a lack of correlation.
Response of Patient Pulmonary Artery ECs to Thrombin
To investigate a possible abnormality in the ability of patient pulmonary artery ECs to respond to stimuli and produce appropriate amounts of either TPA or PAI-1, we compared the levels of these two components in the conditioned media of thrombin-stimulated patient pulmonary artery ECs with those of thrombin-stimulated donor pulmonary artery ECs. Fig 3 shows the data obtained using third-passage ECs cultured in FBS from patients with chronic thromboembolic pulmonary hypertension (n= 12) and from donors (n=5). Although levels for TPA antigen in EC-conditioned media increased with each subsequent passage (see inset in Fig  2A) , thrombin stimulated the production of TPA antigen similarly in ECs isolated from patient pulmonary artery and donor pulmonary artery (Fig 3A; P=.6) . Moreover, the changes in PAI-1 activity in the conditioned media of patient pulmonary artery ECs treated with thrombin were comparable to the values obtained by stimulating donor pulmonary artery ECs with this agent (Fig 3B; P=.5 ). To demonstrate that the observed changes were due to the proteolytic activity of thrombin, parallel experiments were performed using thrombin that had been preincubated with hirudin. Under these conditions, no increase in TPA and PAI-1 levels in the conditioned media was observed (data not shown).
Discussion
A causal role of the fibrinolytic system in arterial and venous thrombosis has been suggested by data from a number of laboratories.27-30 Our previous study of the endogenous fibrinolytic system in patients with chronic thromboembolic pulmonary hypertension21 revealed neither an excess of PAI-1 activity in peripheral blood nor a blunted rise in TPA following venous occlusion. However, the presence of elevated plasma levels of TPA/PAI-1 raised the possibility that a local abnormality in the fibrinolytic system existed within the pulmonary vasculature. Therefore, we initiated a study to investigate the production and secretion of these proteins in pulmonary arterial ECs cultured from a series of patients.
Initial experiments examined the levels of fibrinolytic proteins in primary pulmonary arterial EC cultures. Our data show no statistical differences in the basal levels of TPA antigen and PAI-1 activity in the media conditioned by ECs cultured from patients with chronic thromboembolic pulmonary hypertension and from organ donors (Fig 2) Fig 2A and 2B ), there were no significant differences when the values were analyzed by ANOVA. We did observe a significant increase in TPA antigen and a decrease in PAI-1 activity within the first three passages of patient ECs, which agree with data that describe progressive changes of the EC fibrinolytic phenotype in vitro. 35 Our results emphasize the importance of standardizing data derived from cultured ECs to the days in culture and the number of passages. When experiments were performed using FBS as the serum source, patient ECconditioned media were found to contain significantly more PAI-1 activity as well as PAI-1 antigen (data not shown). These data are in accord with the report of Sawdey et a136 indicating that growth conditions play an important role in the levels of TPA and PAI-1 secreted from cultured vascular ECs.
To gain information about the ability of patient ECs to respond to a secretory stimulus, we added thrombin to the culture media in increasing concentrations. Thrombin, which has been reported to stimulate the production of both TPA37-39 and PAI-1,39.40 was selected because it can be anticipated that this enzyme will be present in the local environment of a thrombus. Our results indicate that TPA antigen and PAI-1 activity were increased by thrombin treatment of both patient and donor ECs. The decrease in PAI-1 activity in Fig 3   (B) Presently, most published studies analyzing the secretion of proteins from cultured human ECs have been performed on material derived from either umbilical cords, autopsies, or organ donors.32-34 This is the first study containing information about ECs grown from the main pulmonary arteries of a well-defined series of patients with chronic proximal pulmonary arterial thromboemboli. Our data suggest that a basic abnormality in the production of either TPA or PAI-1 does not exist in the pulmonary ECs of these patients. Furthermore, we have directly compared two key fibrinolytic proteins in patient plasma and EC-conditioned media. The lack of correlation between the TPA/PAI-1 levels in a patient's plasma and the EC-conditioned media is in accord with current information suggesting that plasma TPA/PAI-1 levels result from a balance between the production by ECs, the formation of complexes in a plasma milieu and on cell surfaces, and the clearance of these components in the systemic and hepatic system.16b42 Therefore, current experiments by our group are directed at determining if a fibrinolytic imbalance occurs in the local environment of the thromboemboli in vivo. Preliminary immunohistochemical and in situ hybridization studies43 indicate that PAI-1 expression is elevated in specific cells within the throm- Thrombin UlmI  FIG 3 . Plots of effect of thrombin on tissue-type plasminogen activator (TPA) antigen and type 1 plasminogen activator inhibitor (PAI-1) activity in patient and control endothelial cell (EC)-conditioned media. Third-passage EC monolayers obtained from chronic thromboembolic pulmonary hypertension patients (circles, n=12) and human donors (squares, n=5) were incubated (24 hours at 370C) with the indicated concentrations of thrombin (0 to 10 U/mL), and the resulting conditioned media were assayed for TPA antigen (A) and PAI-1 activity (B) as described in "Methods." Data are expressed as the fold increase over baseline (ie, level 
